9 completed. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
| Phase 2 | 1 | Completed 1 |
Follow HIBERIX™: new trials by email Literature Review of HIBERIX™ trials Research Report on HIBERIX™
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Prevnar 13™, V114, RotaTeq™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 900 | 2018-10-18 | 2023-01-17 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine Infanrix™-IPV+Hib, Infanrix™ IPV, Hiberix™ - Poliomyelitis, Tetanus | Phase 3 | Completed | GlaxoSmithKline | 454 | 2011-03-04 | 2019-11-27 |
| Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children Infanrix™, Hiberix™ - Acellular Pertussis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 467 | 2008-06-07 | 2018-06-06 |
| Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Haemophilus influenzae type b and meningococcal serogroup C (vaccine), Priorix™, Hiberix™ - Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Completed | GlaxoSmithKline | 433 | 2006-06-01 | 2018-08-24 |
| Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects Tritanrix™- HepB, Hiberix™, Mencevax™ ACW - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 168 | 2006-04-19 | 2018-06-06 |
| Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study Tritanrix™- HepB, Hiberix™, Mencevax™ ACWY - Infections, Meningococcal | Phase 3 | Completed | GlaxoSmithKline | 296 | 2006-02-01 | 2018-06-06 |
| Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants Tritanrix™-HepB/Hiberix™ Kft., Tritanrix™-HepB/Hiberix™, Hiberix™ - Whole Cell Pertussis, Diphtheria | Phase 3 | Completed | GlaxoSmithKline | 745 | 2005-02-10 | 2018-06-06 |
| Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™ Tritanrix™-HepB low thio /, Hib 2.5, Tritanrix™-HepB - Haemophilus Influenzae Type b | Phase 2 | Completed | GlaxoSmithKline | 192 | 2003-08-01 | 2016-09-09 |
Haemophilus Infections (6) · Tetanus (6) · Diphtheria (4) · Hepatitis B (4) · Whooping Cough (3) · Meningococcal Infections (2) · Pneumococcal Infections (2) · Poliomyelitis (1)
GlaxoSmithKline (7) · Merck Sharp & Dohme LLC (2)
Philippines (3) · Puerto Rico (2) · Thailand (2) · Turkey (Türkiye) (2) · United States (2) · Australia (1) · China (1) · South Africa (1) · South Korea (1)
PMID 20657177, PMID 36522265, PMID 36621410, PMID 37846456
2018 (2)